icon-folder.gif   Conference Reports for NATAP  
  EASL 45th Annual Meeting
April 14-18, 2010
Vienna, Austria
Back grey_arrow_rt.gif
High Dose Pegasys/rbv can improve SVR: Impact of higher doses of peginterferon alfa-2a and ribavirin on RVR, cEVR and SVR in HCV G1 patients with viral loads ≥400 000 IU/mL weighing ≥85 kg
  Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
K.R. Reddy,1 M.L. Shiffman,2 M. Rodriguez-Torres,3 D. Abdurakhmanov,4 I. Bakulin,5 G.F. Silva,6 H. Cheinquer,7 M. Rabbia,8 M. McKenna,9 A. Tietz,10 S.A. Harrison,11 on behalf of the PROGRESS Study Investigators 1Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 2Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, USA; 3Fundacion de Investigacion de Diego, Santurce, PR, USA; 4Moscow Medical Academy, Moscow, Russia; 5State Postgraduate Medical Institute, Ministry of Defence of the Russian Federation, Moscow, Russia; 6Botucatu School of Medicine, Botucatu, Brazil; 7Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; 8Roche, Nutley, NJ, USA; 9Roche, Welwyn, UK; 10Roche, Basel, Switzerland; 11Brooke Army Medical Center, Houston, TX, USA This research was funded by Roche, Basel, Switzerland

Figure 1. PROGRESS study design

Figure 2. Virological response rates for the four treatment arms

Figure 3. SVR rates in patients receiving ≥80% of the cumulative dose of peginterferon alfa-2a and ribavirin

Figure 4. Predictors of SVR

Figure 5. SVR rates according to on-treatment responses

Figure 6. SVR rates according to (A) baseline NAS, (B) baseline steatosis score, (C) baseline homeostasis model of assessment-insulin resistance (HOMA-IR) and (D) baseline body weight